The Coronary Circulation as a Target of Cardioprotection

Circulation Research

Volumn 118, Issue 10, 2016, Pages 1643-1658

  Heusch, Gerd ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

coronary artery disease; coronary occlusion; hemorrhage; myocardial infarction; reperfusion injury

Indexed keywords

ABCIXIMAB; ADENOSINE; ATRIAL NATRIURETIC FACTOR; BRADYKININ; BRAIN NATRIURETIC PEPTIDE; CELL ADHESION MOLECULE; CONTRACTILE PROTEIN; CYCLOSPORIN A; ESMOLOL; EXENDIN 4; GADOLINIUM; GLUCAGON LIKE PEPTIDE 1; MANNITOL; METOPROLOL; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; REACTIVE OXYGEN METABOLITE; SELECTIN; SIMVASTATIN; SPHINGOSINE 1 PHOSPHATE; TRIPHENYLTETRAZOLIUM; TUMOR NECROSIS FACTOR ALPHA; CARDIOTONIC AGENT;

ACUTE HEART INFARCTION; ATRIAL FIBRILLATION; BLEEDING; BLOOD VESSEL PERMEABILITY; CELL AGGREGATION; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY COLLATERAL CIRCULATION; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY DILATATION; CORONARY ARTERY OCCLUSION; CORONARY FLOW RESERVE; COUNTERPULSATION; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE DEFORMABILITY; EXCITATION CONTRACTION COUPLING; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HEART RATE; HUMAN; INTRAAORTIC BALLOON PUMP; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; MICROCIRCULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; PERFUSION PRESSURE; PHASE 3 CLINICAL TRIAL (TOPIC); PLATELET REACTIVITY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SARCOPLASMIC RETICULUM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION; VASODILATATION; VASOMOTION; VENULE; ANIMAL; DRUG EFFECTS; MYOCARDIAL ISCHEMIA;

ANIMALS; CARDIOTONIC AGENTS; CORONARY CIRCULATION; HUMANS; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; MYOCARDIAL ISCHEMIA;

EID: 84968764909     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.308640     Document Type: Review

References (250)

1. Heusch G, Schulz R. Neglect of the coronary circulation: some critical remarks on problems in the translation of cardioprotection. Cardiovasc Res. 2009;84:11-14. doi: 10. 1093/cvr/cvp210.
2. Heusch G, Kleinbongard P, Skyschally A, Levkau B, Schulz R, Erbel R. The coronary circulation in cardioprotection: more than just one confounder. Cardiovasc Res. 2012;94:237-245. doi: 10. 1093/cvr/cvr271.
3. Thygesen K, Alpert JS, Jaffe AS, et al; Writing Group on the Joint ESC/ ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction; ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551-2567. doi: 10. 1093/eurheartj/ehs184.
4. Heusch G. Postconditioning: old wine in a new bottle? J Am Coll Cardiol. 2004;44:1111-1112. doi: 10. 1016/j. jacc. 2004. 06. 013.
5. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121-1135. doi: 10. 1056/NEJMra071667.
6. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: A neglected therapeutic target. J Clin Invest. 2013;123:92-100. doi: 10. 1172/ JCI62874.
7. Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res. 2015;116:674-699. doi: 10. 1161/CIRCRESAHA. 116. 305348.
8. Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet. 2013;381:166-175. doi: 10. 1016/S0140-6736(12)60916-7.
9. Mehta LS, Beckie TM, DeVon HA, Grines CL, Krumholz HM, Johnson MN, Lindley KJ, Vaccarino V, Wang TY, Watson KE, Wenger NK; American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Cardiovascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Acute myocardial infarction in women: A scientific statement from the American Heart Association. Circulation. 2016;133:916-947. doi: 10. 1161/CIR. 0000000000000351.
10. Sack MN, Murphy E. The role of comorbidities in cardioprotection. J Cardiovasc Pharmacol Ther. 2011;16:267-272. doi: 10. 1177/ 1074248411408313.
11. Pepine CJ, Ferdinand KC, Shaw LJ, Light-McGroary KA, Shah RU, Gulati M, Duvernoy C, Walsh MN, Bairey Merz CN; ACC CVD in Women Committee. Emergence of nonobstructive coronary artery disease: A woman's problem and need for change in definition on angiography. J Am Coll Cardiol. 2015;66:1918-1933. doi: 10. 1016/j. jacc. 2015. 08. 876.
12. Skyschally A, Schulz R, Heusch G. Pathophysiology of myocardial infarction: protection by ischemic pre-and postconditioning. Herz. 2008;33:88-100. doi: 10. 1007/s00059-008-3101-9.
13. Ibanez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 2015;65:1454-1471. doi: 10. 1016/j. jacc. 2015. 02. 032.
14. Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SF. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest. 1975;56:978-985. doi: 10. 1172/JCI108178.
15. Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation. 1982;66:1146-1149.
16. Bolli R. Mechanism of myocardial "stunning". Circulation. 1990;82:723-738.
17. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev. 1999;79:609-634.
18. Heusch G. Hibernating myocardium. Physiol Rev. 1998;78:1055-1085.
19. Heusch G, Schulz R, Rahimtoola SH. Myocardial hibernation: A delicate balance. Am J Physiol Heart Circ Physiol. 2005;288:H984-H999. doi: 10. 1152/ajpheart. 01109. 2004.
20. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977;56:786-794.
21. Reimer KA, Jennings RB. The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest. 1979;40:633-644.
22. Schaper W, Gorge G, Winkler B, Schaper J. The collateral circulation of the heart. Prog Cardiovasc Dis. 1988;31:57-77.
23. Horneffer PJ, Healy B, Gott VL, Gardner TJ. The rapid evolution of a myocardial infarction in an end-artery coronary preparation. Circulation. 1987;76:V39-V42.
24. Pich S, Klein HH, Lindert S, Nebendahl K, Kreuzer H. Cell death in ischemic, reperfused porcine hearts: A histochemical and functional study. Basic Res Cardiol. 1988;83:550-559.
25. Yang XM, Liu Y, Liu Y, Tandon N, Kambayashi J, Downey JM, Cohen MV. Attenuation of infarction in cynomolgus monkeys: preconditioning and postconditioning. Basic Res Cardiol. 2010;105:119-128. doi: 10. 1007/s00395-009-0050-2.
26. Cinca J, Carreno A, Mont L, Blanch P, Soler-Soler J. Neurally mediated negative inotropic effect impairs myocardial function during cholinergic coronary vasoconstriction in pigs. Circulation. 1996;94:1101-1108.
27. Oudiz R, Heusch G, Guth BD. Selective alpha1-and alpha2-adrenergic coronary vasoconstriction in anesthetized swine. Faseb J. 1989;3:A896-(abstr.).
28. Heusch G, Baumgart D, Camici P, Chilian W, Gregorini L, Hess O, Indolfi C, Rimoldi O. Alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation. 2000;101:689-694.
29. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315:1046-1051. doi: 10. 1056/NEJM198610233151702.
30. Hedstrom E, Engblom H, Frogner F, Astrom-Olsson K, Ohlin H, Jovinge S, Arheden H. Infarct evolution in man studied in patients with first-time coronary occlusion in comparison to different species-implications for assessment of myocardial salvage. J Cardiovasc Magn Reson. 2009;11:38. doi: 10. 1186/1532-429X-11-38.
31. Desmet W, Bogaert J, Dubois C, Sinnaeve P, Adriaenssens T, Pappas C, Ganame J, Dymarkowski S, Janssens S, Belmans A, Van de Werf F. Highdose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J. 2011;32:867-877. doi: 10. 1093/eurheartj/ehq492.
32. Ibanez B, Macaya C, Sanchez-Brunete V, et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: The Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. Circulation. 2013;128:1495-1503. doi: 10. 1161/CIRCULATIONAHA. 113. 003653.
33. Schomig A, Mehilli J, Antoniucci D, et al; Beyond 12 hours Reperfusion AlternatiVe Evaluation (BRAVE-2) Trial Investigators. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: A randomized controlled trial. JAMA. 2005;293:2865-2872. doi: 10. 1001/jama. 293. 23. 2865.
34. Ndrepepa G, Kastrati A, Mehilli J, Antoniucci D, Schomig A. Mechanical reperfusion and long-term mortality in patients with acute myocardial infarction presenting 12 to 48 hours from onset of symptoms. JAMA. 2009;301:487-488. doi: 10. 1001/jama. 2009. 32.
35. Kleinbongard P, Heusch G. Extracellular signalling molecules in the ischaemic/ reperfused heart-druggable and translatable for cardioprotection? Br J Pharmacol. 2015;172:2010-2025. doi: 10. 1111/bph. 12902.
36. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol. 2008;153:1589-1601. doi: 10. 1038/sj. bjp. 0707673.
37. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124-1136.
38. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003;285:H579-H588. doi: 10. 1152/ ajpheart. 01064. 2002.
39. Maroko PR, Libby P, Ginks WR, Bloor CM, Shell WE, Sobel BE, Ross J Jr. Coronary artery reperfusion. I. Early effects on local myocardial function and the extent of myocardial necrosis. J Clin Invest. 1972;51:2710-2716. doi: 10. 1172/JCI107090.
40. Ginks WR, Sybers HD, Maroko PR, Covell JW, Sobel BE, Ross J Jr. Coronary artery reperfusion. II. Reduction of myocardial infarct size at 1 week after the coronary occlusion. J Clin Invest. 1972;51:2717-2723. doi: 10. 1172/JCI107091.
41. Hartzler GO, Rutherford BD, McConahay DR, Johnson WL Jr, McCallister BD, Gura GM Jr, Conn RC, Crockett JE. Percutaneous transluminal coronary angioplasty with and without thrombolytic therapy for treatment of acute myocardial infarction. Am Heart J. 1983;106:965-973.
42. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet. 1986;1:397-402.
43. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute mycardial infarction: ISIS-1. Lancet. 1986;2:57-69.
44. Krug A, Du Mesnil de Rochemont, Korb G. Blood supply of the myocardium after temporary coronary occlusion. Circ Res. 1966;19:57-62.
45. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54:1496-1508. doi: 10. 1172/JCI107898.
46. Przyklenk K. Lethal myocardial "reperfusion injury": The opinions of good men. J Thromb Thrombolysis. 1997;4:5-6.
47. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, Aupetit JF, Bonnefoy E, Finet G, Andre-Fouet X, Ovize M. Postconditioning the human heart. Circulation. 2005;112:2143-2148. doi: 10. 1161/ CIRCULATIONAHA. 105. 558122.
48. Heusch G. Reduction of infarct size by ischaemic post-conditioning in humans: fact or fiction? Eur Heart J. 2012;33:13-15. doi: 10. 1093/ eurheartj/ehr341.
49. Okamoto F, Allen BS, Buckberg GD, Bugyi H, Leaf J. Reperfusion conditions: importance of ensuring gentle versus sudden reperfusion during relief of coronary occlusion. J Thorac Cardiovasc Surg. 1986;92:613-620.
50. Ferrera R, Benhabbouche S, Da Silva CC, Alam MR, Ovize M. Delayed low pressure at reperfusion: A new approach for cardioprotection. J Thorac Cardiovasc Surg. 2015;150:1641-8. e2. doi: 10. 1016/j. jtcvs. 2015. 08. 053.
51. Musiolik J, van Caster P, Skyschally A, Boengler K, Gres P, Schulz R, Heusch G. Reduction of infarct size by gentle reperfusion without activation of reperfusion injury salvage kinases in pigs. Cardiovasc Res. 2010;85:110-117. doi: 10. 1093/cvr/cvp271.
52. Heusch G. Treatment of myocardial ischemia/reperfusion injury by ischemic and pharmacological postconditioning. Compr Physiol. 2015;5:1123-1145. doi: 10. 1002/cphy. c140075.
53. Schaper W, Frenzel H, Hort W. Experimental coronary artery occlusion. I. Measurement of infarct size. Basic Res Cardiol. 1979;74:46-53.
54. Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, Corday E, Ganz W. Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J. 1981;101:593-600.
55. Kloner RA. No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharmacol Ther. 2011;16:244-250. doi: 10. 1177/ 1074248411405990.
56. Sheehan FH, Braunwald E, Canner P, Dodge HT, Gore J, Van Natta P, Passamani ER, Williams DO, Zaret B. The effect of intravenous thrombolytic therapy on left ventricular function: A report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. Circulation. 1987;75:817-829.
57. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E. TIMI frame count: A quantitative method of assessing coronary artery flow. Circulation. 1996;93:879-888.
58. van 't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation. 1998;97:2302-2306.
59. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54:281-292. doi: 10. 1016/j. jacc. 2009. 03. 054.
60. Dauber IM, VanBenthuysen KM, McMurtry IF, Wheeler GS, Lesnefsky EJ, Horwitz LD, Weil JV. Functional coronary microvascular injury evident as increased permeability due to brief ischemia and reperfusion. Circ Res. 1990;66:986-998.
61. Garcia-Dorado D, Oliveras J, Gili J, Sanz E, Perez-Villa F, Barrabes J, Carreras MJ, Solares J, Soler-Soler J. Analysis of myocardial oedema by magnetic resonance imaging early after coronary artery occlusion with or without reperfusion. Cardiovasc Res. 1993;27:1462-1469.
62. Garcia-Dorado D, Oliveras J. Myocardial oedema: A preventable cause of reperfusion injury? Cardiovasc Res. 1993;27:1555-1563.
63. Abdel-Aty H, Cocker M, Meek C, Tyberg JV, Friedrich MG. Edema as a very early marker for acute myocardial ischemia: A cardiovascular magnetic resonance study. J Am Coll Cardiol. 2009;53:1194-1201. doi: 10. 1016/j. jacc. 2008. 10. 065.
64. Garcia-Dorado D, Andres-Villarreal M, Ruiz-Meana M, Inserte J, Barba I. Myocardial edema: A translational view. J Mol Cell Cardiol. 2012;52:931-939. doi: 10. 1016/j. yjmcc. 2012. 01. 010.
65. Noll T, Muhs A, Besselmann M, Watanabe H, Piper HM. Initiation of hyperpermeability in energy-depleted coronary endothelial monolayers. Am J Physiol. 1995;268:H1462-H1470.
66. Becker BF, Chappell D, Jacob M. Endothelial glycocalyx and coronary vascular permeability: The fringe benefit. Basic Res Cardiol. 2010;105:687-701. doi: 10. 1007/s00395-010-0118-z.
67. Juchem G, Weiss DR, Knott M, Senftl A, Forch S, Fischlein T, Kreuzer E, Reichart B, Laufer S, Nees S. Regulation of coronary venular barrier function by blood borne inflammatory mediators and pharmacological tools: insights from novel microvascular wall models. Am J Physiol Heart Circ Physiol. 2012;302:H567-H581. doi: 10. 1152/ajpheart. 00360. 2011.
68. Kuhne W, Besselmann M, Noll T, Muhs A, Watanabe H, Piper HM. Disintegration of cytoskeletal structure of actin filaments in energy-depleted endothelial cells. Am J Physiol. 1993;264:H1599-H1608.
69. Galaup A, Gomez E, Souktani R, et al. Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4. Circulation. 2012;125:140-149. doi: 10. 1161/ CIRCULATIONAHA. 111. 049072.
70. Li Z, Jin ZQ. Ischemic preconditioning enhances integrity of coronary endothelial tight junctions. Biochem Biophys Res Commun. 2012;425:630-635. doi: 10. 1016/j. bbrc. 2012. 07. 130.
71. Aslam M, Schluter KD, Rohrbach S, Rafiq A, Nazli S, Piper HM, Noll T, Schulz R, Gunduz D. Hypoxia-reoxygenation-induced endothelial barrier failure: role of RhoA, Rac1 and myosin light chain kinase. J Physiol. 2013;591:461-473. doi: 10. 1113/jphysiol. 2012. 237834.
72. Gunduz D, Aslam M, Krieger U, Becker L, Grebe M, Arshad M, Sedding DG, Hartel FV, Abdallah Y, Piper HM, Voss RK, Noll T. Opposing effects of ATP and adenosine on barrier function of rat coronary microvasculature. J Mol Cell Cardiol. 2012;52:962-970. doi: 10. 1016/j. yjmcc. 2012. 01. 003.
73. van den Berg BM, Vink H, Spaan JA. The endothelial glycocalyx protects against myocardial edema. Circ Res. 2003;92:592-594. doi: 10. 1161/01. RES. 0000065917. 53950. 75.
74. Annecke T, Fischer J, Hartmann H, Tschoep J, Rehm M, Conzen P, Sommerhoff CP, Becker BF. Shedding of the coronary endothelial glycocalyx: effects of hypoxia/reoxygenation vs ischaemia/reperfusion. Br J Anaesth. 2011;107:679-686. doi: 10. 1093/bja/aer269.
75. Chappell D, Hofmann-Kiefer K, Jacob M, Rehm M, Briegel J, Welsch U, Conzen P, Becker BF. TNF-alpha induced shedding of the endothelial glycocalyx is prevented by hydrocortisone and antithrombin. Basic Res Cardiol. 2009;104:78-89. doi: 10. 1007/s00395-008-0749-5.
76. Chappell D, Dorfler N, Jacob M, Rehm M, Welsch U, Conzen P, Becker BF. Glycocalyx protection reduces leukocyte adhesion after ischemia/reperfusion. Shock. 2010;34:133-139. doi: 10. 1097/SHK. 0b013e3181cdc363.
77. Chappell D, Brettner F, Doerfler N, Jacob M, Rehm M, Bruegger D, Conzen P, Jacob B, Becker BF. Protection of glycocalyx decreases platelet adhesion after ischaemia/reperfusion: An animal study. Eur J Anaesthesiol. 2014;31:474-481. doi: 10. 1097/EJA. 0000000000000085.
78. Bruegger D, Rehm M, Jacob M, Chappell D, Stoeckelhuber M, Welsch U, Conzen P, Becker BF. Exogenous nitric oxide requires an endothelial glycocalyx to prevent postischemic coronary vascular leak in guinea pig hearts. Crit Care. 2008;12:R73. doi: 10. 1186/cc6913.
79. Fernandez-Jimenez R, Garcia-Prieto J, Sanchez-Gonzalez J, Aguero J, Lopez-Martin GJ, Galan-Arriola C, Molina-Iracheta A, Doohan R, Fuster V, Ibanez B. Pathophysiology underlying the bimodal edema phenomenon after myocardial ischemia/reperfusion. J Am Coll Cardiol. 2015;66:816-828. doi: 10. 1016/j. jacc. 2015. 06. 023.
80. Aletras AH, Tilak GS, Natanzon A, Hsu LY, Gonzalez FM, Hoyt RF Jr, Arai AE. Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. Circulation. 2006;113:1865-1870. doi: 10. 1161/CIRCULATIONAHA. 105. 576025.
81. Mewton N, Rapacchi S, Augeul L, Ferrera R, Loufouat J, Boussel L, Micolich A, Rioufol G, Revel D, Ovize M, Croisille P. Determination of the myocardial area at risk with pre-versus post-reperfusion imaging techniques in the pig model. Basic Res Cardiol. 2011;106:1247-1257. doi: 10. 1007/s00395-011-0214-8.
82. Heusch P, Nensa F, Heusch G. Is MRI really the gold standard for the quantification of salvage from myocardial infarction? Circ Res. 2015;117:222-224. doi: 10. 1161/CIRCRESAHA. 117. 306929.
83. Frame LH, Powell WJ Jr. Progressive perfusion impairment during prolonged low flow myocardial ischemia in dogs. Circ Res. 1976;39:269-276.
84. Manciet LH, Poole DC, McDonagh PF, Copeland JG, Mathieu-Costello O. Microvascular compression during myocardial ischemia: mechanistic basis for no-reflow phenomenon. Am J Physiol. 1994;266:H1541-H1550.
85. Aversano T, Becker LC. Persistence of coronary vasodilator reserve despite functionally significant flow reduction. Am J Physiol. 1985;248:H403-H411.
86. Canty JM Jr, Klocke FJ. Reduced regional myocardial perfusion in the presence of pharmacologic vasodilator reserve. Circulation. 1985;71:370-377.
87. Gross GJ, O'Rourke ST, Pelc LR, Warltier DC. Myocardial and endothelial dysfunction after multiple, brief coronary occlusions: role of oxygen radicals. Am J Physiol. 1992;263:H1703-H1709.
88. Ehring T, Krajcar M, Baumgart D, Kompa S, Hummelgen M, Heusch G. Cholinergic and alpha-adrenergic coronary vasomotion [corrected] with increasing ischemia-reperfusion injury. Am J Physiol. 1995;268:H886-H894.
89. Heusch G, Deussen A. The effects of cardiac sympathetic nerve stimulation on perfusion of stenotic coronary arteries in the dog. Circ Res. 1983;53:8-15.
90. Heusch G, Deussen A, Thamer V. Cardiac sympathetic nerve activity and progressive vasoconstriction distal to coronary stenoses: feed-back aggravation of myocardial ischemia. J Auton Nerv Syst. 1985;13:311-326.
91. Baumgart D, Haude M, Gorge G, Liu F, Ge J, Grosse-Eggebrecht C, Erbel R, Heusch G. Augmented alpha-adrenergic constriction of atherosclerotic human coronary arteries. Circulation. 1999;99:2090-2097.
92. Gregorini L, Marco J, Kozakova M, Palombo C, Anguissola GB, Marco I, Bernies M, Cassagneau B, Distante A, Bossi IM, Fajadet J, Heusch G. Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation. 1999;99:482-490.
93. Gregorini L, Marco J, Farah B, Bernies M, Palombo C, Kozakova M, Bossi IM, Cassagneau B, Fajadet J, Di Mario C, Albiero R, Cugno M, Grossi A, Heusch G. Effects of selective alpha1-and alpha2-adrenergic blockade on coronary flow reserve after coronary stenting. Circulation. 2002;106:2901-2907.
94. Leineweber K, Bose D, Vogelsang M, Haude M, Erbel R, Heusch G. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. J Am Coll Cardiol. 2006;47:981-986. doi: 10. 1016/j. jacc. 2005. 10. 053.
95. Kleinbongard P, Bose D, Baars T, Mohlenkamp S, Konorza T, Schoner S, Elter-Schulz M, Eggebrecht H, Degen H, Haude M, Levkau B, Schulz R, Erbel R, Heusch G. Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. Circ Res. 2011;108:344-352. doi: 10. 1161/CIRCRESAHA. 110. 235713.
96. Kleinbongard P, Baars T, Mohlenkamp S, Kahlert P, Erbel R, Heusch G. Aspirate from human stented native coronary arteries vs. saphenous vein grafts: more endothelin but less particulate debris. Am J Physiol Heart Circ Physiol. 2013;305:H1222-H1229. doi: 10. 1152/ ajpheart. 00358. 2013.
97. Ku DD. Coronary vascular reactivity after acute myocardial ischemia. Science. 1982;218:576-578.
98. Bolli R, Triana JF, Jeroudi MO. Prolonged impairment of coronary vasodilation after reversible ischemia. Evidence for microvascular "stunning". Circ Res. 1990;67:332-343.
99. Mills I, Fallon JT, Wrenn D, Sasken H, Gray W, Bier J, Levine D, Berman S, Gilson M, Gewirtz H. Adaptive responses of coronary circulation and myocardium to chronic reduction in perfusion pressure and flow. Am J Physiol. 1994;266:H447-H457.
100. Sorop O, Merkus D, de Beer VJ, Houweling B, Pistea A, McFalls EO, Boomsma F, van Beusekom HM, van der Giessen WJ, VanBavel E, Duncker DJ. Functional and structural adaptations of coronary microvessels distal to a chronic coronary artery stenosis. Circ Res. 2008;102:795-803. doi: 10. 1161/CIRCRESAHA. 108. 172528.
101. Heusch G, Kleinbongard P, Bose D, Levkau B, Haude M, Schulz R, Erbel R. Coronary microembolization: from bedside to bench and back to bedside. Circulation. 2009;120:1822-1836. doi: 10. 1161/ CIRCULATIONAHA. 109. 888784.
102. Dorge H, Neumann T, Behrends M, Skyschally A, Schulz R, Kasper C, Erbel R, Heusch G. Perfusion-contraction mismatch with coronary microvascular obstruction: role of inflammation. Am J Physiol Heart Circ Physiol. 2000;279:H2587-H2592.
103. Skyschally A, Gres P, Heusch P, Martin C, Haude M, Erbel R, Schulz R, Heusch G. Preinfarction angina: no interference of coronary microembolization with acute ischemic preconditioning. J Mol Cell Cardiol. 2005;39:355-361. doi: 10. 1016/j. yjmcc. 2005. 04. 003.
104. Skyschally A, Walter B, Heusch G. Coronary microembolization during early reperfusion: infarct extension, but protection by ischaemic postconditioning. Eur Heart J. 2013;34:3314-3321. doi: 10. 1093/eurheartj/ ehs434.
105. Herrmann J, Haude M, Lerman A, Schulz R, Volbracht L, Ge J, Schmermund A, Wieneke H, von Birgelen C, Eggebrecht H, Baumgart D, Heusch G, Erbel R. Abnormal coronary flow velocity reserve after coronary intervention is associated with cardiac marker elevation. Circulation. 2001;103:2339-2345.
106. Skyschally A, Schulz R, Erbel R, Heusch G. Reduced coronary and inotropic reserves with coronary microembolization. Am J Physiol Heart Circ Physiol. 2002;282:H611-H614. doi: 10. 1152/ajpheart. 00797. 2001.
107. Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, Kaya U, Popma JJ, Ho KK, Kuntz RE; Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 2002;105:1285-1290.
108. Lins M, Heuer H, Haude M, Braun P, Stahl F, Franz N, Simon R; FIRST Trial Investigators. Distal embolic protection during percutaneous intervention of aorto-coronary venous bypass grafts: The FIRST Trial. Clin Res Cardiol. 2007;96:738-742. doi: 10. 1007/s00392-007-0553-5.
109. Sheridan FM, Dauber IM, McMurtry IF, Lesnefsky EJ, Horwitz LD. Role of leukocytes in coronary vascular endothelial injury due to ischemia and reperfusion. Circ Res. 1991;69:1566-1574.
110. Kogaki S, Sawa Y, Sano T, Matsushita T, Ohata T, Kurotobi S, Tojo SJ, Matsuda H, Okada S. Selectin on activated platelets enhances neutrophil endothelial adherence in myocardial reperfusion injury. Cardiovasc Res. 1999;43:968-973.
111. Kupatt C, Wichels R, Horstkotte J, Krombach F, Habazettl H, Boekstegers P. Molecular mechanisms of platelet-mediated leukocyte recruitment during myocardial reperfusion. J Leukoc Biol. 2002;72:455-461.
112. Barrabes JA, Garcia-Dorado D, Mirabet M, Inserte J, Agullo L, Soriano B, Massaguer A, Padilla F, Lidon RM, Soler-Soler J. Antagonism of selectin function attenuates microvascular platelet deposition and plateletmediated myocardial injury after transient ischemia. J Am Coll Cardiol. 2005;45:293-299. doi: 10. 1016/j. jacc. 2004. 09. 068.
113. Chukwuemeka AO, Brown KA, Venn GE, Chambers DJ. Changes in P-selectin expression on cardiac microvessels in blood-perfused rat hearts subjected to ischemia-reperfusion. Ann Thorac Surg. 2005;79:204-211. doi: 10. 1016/j. Athoracsur. 2004. 06. 105.
114. Barrabes JA, Mirabet M, Agullo L, Figueras J, Pizcueta P, Garcia-Dorado D. Platelet deposition in remote cardiac regions after coronary occlusion. Eur J Clin Invest. 2007;37:939-946. doi: 10. 1111/j. 1365-2362. 2007. 01883. x.
115. Barrabes JA, Inserte J, Agullo L, Alonso A, Mirabet M, Garcia-Dorado D. Microvascular thrombosis: An exciting but elusive therapeutic target in reperfused acute myocardial infarction. Cardiovasc Hematol Disord Drug Targets. 2010;10:273-283.
116. Driesen RB, Zalewski J, Vanden Driessche N, Vermeulen K, Bogaert J, Sipido KR, Van de Werf F, Claus P. Histological correlate of a cardiac magnetic resonance imaged microvascular obstruction in a porcine model of ischemia-reperfusion. Cardiovasc Pathol. 2012;21:129-131. doi: 10. 1016/j. carpath. 2011. 07. 008.
117. Higginson LA, White F, Heggtveit HA, Sanders TM, Bloor CM, Covell JW. Determinants of myocardial hemorrhage after coronary reperfusion in the anesthetized dog. Circulation. 1982;65:62-69.
118. Higginson LA, Beanlands DS, Nair RC, Temple V, Sheldrick K. The time course and characterization of myocardial hemorrhage after coronary reperfusion in the anesthetized dog. Circulation. 1983;67:1024-1031.
119. Beek AM, Nijveldt R, van Rossum AC. Intramyocardial hemorrhage and microvascular obstruction after primary percutaneous coronary intervention. Int J Cardiovasc Imaging. 2010;26:49-55. doi: 10. 1007/ s10554-009-9499-1.
120. Marra MP, Cacciavillani L, Corbetti F, Tarantini G, Ramondo AB, Napodano M, Basso C, Lacognata C, Marzari A, Maddalena F, Iliceto S. The contribution of intramyocardial hemorrhage to the "no-reflow phenomenon": A study performed by cardiac magnetic resonance. Echocardiography. 2010;27:1120-1129. doi: 10. 1111/j. 1540-8175. 2010. 01213. x.
121. Bonanad C, Ruiz-Sauri A, Forteza MJ, et al. Microvascular obstruction in the right ventricle in reperfused anterior myocardial infarction. Macroscopic and pathologic evidence in a swine model. Thromb Res. 2013;132:592-598. doi: 10. 1016/j. Thromres. 2013. 08. 009.
122. Robbers LF, Eerenberg ES, Teunissen PF, Jansen MF, Hollander MR, Horrevoets AJ, Knaapen P, Nijveldt R, Heymans MW, Levi MM, van Rossum AC, Niessen HW, Marcu CB, Beek AM, van Royen N. Magnetic resonance imaging-defined areas of microvascular obstruction after acute myocardial infarction represent microvascular destruction and haemorrhage. Eur Heart J. 2013;34:2346-2353. doi: 10. 1093/eurheartj/eht100.
123. Prasad A, Gersh BJ, Mehran R, Brodie BR, Brener SJ, Dizon JM, Lansky AJ, Witzenbichler B, Kornowski R, Guagliumi G, Dudek D, Stone GW. Effect of ischemia duration and door-to-balloon time on myocardial perfusion in ST-segment elevation myocardial infarction: An analysis from HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). JACC Cardiovasc Interv. 2015;8:1966-1974. doi: 10. 1016/j. jcin. 2015. 08. 031.
124. Niccoli G, Scalone G, Lerman A, Crea F. Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J. 2016;37:1024-1033. doi: 10. 1093/eurheartj/ehv484.
125. Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne RA, Pache J, Alger P, Mehilli J, Schomig A, Kastrati A. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010;55:2383-2389. doi: 10. 1016/j. jacc. 2009. 12. 054.
126. Betgem RP, de Waard GA, Nijveldt R, Beek AM, Escaned J, van Royen N. Intramyocardial haemorrhage after acute myocardial infarction. Nat Rev Cardiol. 2015;12:156-167. doi: 10. 1038/nrcardio. 2014. 188.
127. Laude K, Beauchamp P, Thuillez C, Richard V. Endothelial protective effects of preconditioning. Cardiovasc Res. 2002;55:466-473.
128. Di Napoli P, Di Muzio M, Contegiacomo G, Tiloca P, Spoletini L, Di Crecchio A, Gallina S, Barsotti A. [Ischemic preconditioning of the myocardium: The role of changes in the permeability of the coronary microcirculation]. Cardiologia. 1997;42:59-67.
129. Bauer B, Simkhovich BZ, Kloner RA, Przyklenk K. Does preconditioning protect the coronary vasculature from subsequent ischemia/reperfusion injury? Circulation. 1993;88:659-672.
130. Loke KE, Woodman OL. Preconditioning improves myocardial function and reflow, but not vasodilator reactivity, after ischaemia and reperfusion in anaesthetized dogs. Clin Exp Pharmacol Physiol. 1998;25:552-558.
131. Richard V, Kaeffer N, Tron C, Thuillez C. Ischemic preconditioning protects against coronary endothelial dysfunction induced by ischemia and reperfusion. Circulation. 1994;89:1254-1261.
132. Bouchard JF, Lamontagne D. Mechanisms of protection afforded by preconditioning to endothelial function against ischemic injury. Am J Physiol. 1996;271:H1801-H1806.
133. Bouchard JF, Chouinard J, Lamontagne D. Role of kinins in the endothelial protective effect of ischaemic preconditioning. Br J Pharmacol. 1998;123:413-420. doi: 10. 1038/sj. bjp. 0701619.
134. Kurzelewski M, Czarnowska E, Maczewski M, Beresewicz A. Effect of ischemic preconditioning on endothelial dysfunction and granulocyte adhesion in isolated guinea-pig hearts subjected to ischemia/reperfusion. J Physiol Pharmacol. 1999;50:617-628.
135. Thourani VH, Nakamura M, Duarte IG, Bufkin BL, Zhao ZQ, Jordan JE, Shearer ST, Guyton RA, Vinten-Johansen J. Ischemic preconditioning attenuates postischemic coronary artery endothelial dysfunction in a model of minimally invasive direct coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1999;117:383-389. doi: 10. 1016/ S0022-5223(99)70437-X.
136. Merkus D, Stepp DW, Jones DW, Nishikawa Y, Chilian WM. Adenosine preconditions against endothelin-induced constriction of coronary arterioles. Am J Physiol Heart Circ Physiol. 2000;279:H2593-H2597.
137. Tofukuji M, Metais C, Li J, Hariawala MD, Franklin A, Vassileva C, Li J, Simons M, Sellke FW. Effects of ischemic preconditioning on myocardial perfusion, function, and microvascular regulation. Circulation. 1998;98:II-197-II-205.
138. Gattullo D, Linden RJ, Losano G, Pagliaro P, Westerhof N. Ischaemic preconditioning changes the pattern of coronary reactive hyperaemia in the goat: role of adenosine and nitric oxide. Cardiovasc Res. 1999;42:57-64.
139. Posa A, Pavo N, Hemetsberger R, Csonka C, Csont T, Ferdinandy P, Petrasi Z, Varga C, Pavo IJ, Laszlo F Jr, Huber K, Gyongyosi M. Protective effect of ischaemic preconditioning on ischaemia/reperfusion-induced microvascular obstruction determined by on-line measurements of coronary pressure and blood flow in pigs. Thromb Haemost. 2010;103:450-460. doi: 10. 1160/TH09-03-0165.
140. Kaeffer N, Richard V, Francois A, Lallemand F, Henry JP, Thuillez C. Preconditioning prevents chronic reperfusion-induced coronary endothelial dysfunction in rats. Am J Physiol. 1996;271:H842-H849.
141. Laude K, Favre J, Thuillez C, Richard V. NO produced by endothelial NO synthase is a mediator of delayed preconditioning-induced endothelial protection. Am J Physiol Heart Circ Physiol. 2003;284:H2053-H2060. doi: 10. 1152/ajpheart. 00627. 2002.
142. Kim SJ, Zhang X, Xu X, Chen A, Gonzalez JB, Koul S, Vijayan K, Crystal GJ, Vatner SF, Hintze TH. Evidence for enhanced eNOS function in coronary microvessels during the second window of protection. Am J Physiol Heart Circ Physiol. 2007;292:H2152-H2158. doi: 10. 1152/ ajpheart. 00326. 2006.
143. Kaeffer N, Richard V, Thuillez C. Delayed coronary endothelial protection 24 hours after preconditioning: role of free radicals. Circulation. 1997;96:2311-2316.
144. Matsuda N, Morgan KG, Sellke FW. Preconditioning improves cardioplegia-related coronary microvascular smooth muscle hypercontractility: role of KATP channels. J Thorac Cardiovasc Surg. 1999;118:438-445. doi: 10. 1016/S0022-5223(99)70180-7.
145. Skyschally A, Schulz R, Gres P, Konietzka I, Martin C, Haude M, Erbel R, Heusch G. Coronary microembolization does not induce acute preconditioning against infarction in pigs-the role of adenosine. Cardiovasc Res. 2004;63:313-322. doi: 10. 1016/j. cardiores. 2004. 04. 003.
146. Skyschally A, Gres P, Hoffmann S, Haude M, Erbel R, Schulz R, Heusch G. Bidirectional role of tumor necrosis factor-alpha in coronary microembolization: progressive contractile dysfunction versus delayed protection against infarction. Circ Res. 2007;100:140-146. doi: 10. 1161/01. RES. 0000255031. 15793. 86.
147. Heusch G. Nitroglycerin and delayed preconditioning in humans: yet another new mechanism for an old drug? Circulation. 2001;103:2876-2878.
148. Rezkalla SH, Kloner RA. Ischemic preconditioning and preinfarction angina in the clinical arena. Nat Clin Pract Cardiovasc Med. 2004;1:96-102. doi: 10. 1038/ncpcardio0047.
149. Scalone G, Aurigemma C, Tomai F, Corvo P, Battipaglia I, Lanza GA, Crea F. Effect of pre-infarction angina on platelet reactivity in acute myocardial infarction. Int J Cardiol. 2013;167:51-56. doi: 10. 1016/j. ijcard. 2011. 11. 085.
150. Colonna P, Cadeddu C, Montisci R, Ruscazio M, Selem AH, Chen L, Onnis E, Meloni L, Iliceto S. Reduced microvascular and myocardial damage in patients with acute myocardial infarction and preinfarction angina. Am Heart J. 2002;144:796-803.
151. Niccoli G, Scalone G, Cosentino N, Fabretti A, Mirizzi AM, Gramegna M, Panebianco M, Roberto M, Crea F. Protective effect of pre-infarction angina on microvascular obstruction after primary percutaneous coronary intervention is blunted in humans by cardiovascular risk factors. Circ J. 2014;78:1935-1941.
152. Hale SL, Mehra A, Leeka J, Kloner RA. Postconditioning fails to improve no reflow or alter infarct size in an open-chest rabbit model of myocardial ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2008;294:H421-H425. doi: 10. 1152/ajpheart. 00962. 2007.
153. Bodi V, Ruiz-Nodar JM, Feliu E, et al. Effect of ischemic postconditioning on microvascular obstruction in reperfused myocardial infarction. Results of a randomized study in patients and of an experimental model in swine. Int J Cardiol. 2014;175:138-146. doi: 10. 1016/j. ijcard. 2014. 05. 003.
154. Skyschally A, Kleinbongard P, Heusch G. Local and remote ischemic preconditioning reduces myocardial infarct size and microvascular obstruction during reperfusion, whereas ischemic postconditioning only reduces infarct size. Clin Res Cardiol. 2016;105 Suppl. 1:V845.
155. Zhao JL, Yang YJ, You SJ, Cui CJ, Gao RL. Different effects of postconditioning on myocardial no-reflow in the normal and hypercholesterolemic mini-swines. Microvasc Res. 2007;73:137-142. doi: 10. 1016/j. mvr. 2006. 09. 002.
156. Ma X, Zhang X, Li C, Luo M. Effect of postconditioning on coronary blood flow velocity and endothelial function and LV recovery after myocardial infarction. J Interv Cardiol. 2006;19:367-375. doi: 10. 1111/j. 1540-8183. 2006. 00191. x.
157. Ma XJ, Zhang XH, Li CM, Luo M. Effect of postconditioning on coronary blood flow velocity and endothelial function in patients with acute myocardial infarction. Scand Cardiovasc J. 2006;40:327-333. doi: 10. 1080/14017430601047864.
158. Yang XC, Liu Y, Wang LF, Cui L, Wang T, Ge YG, Wang HS, Li WM, Xu L, Ni ZH, Liu SH, Zhang L, Jia HM, Vinten-Johansen J, Zhao ZQ. Reduction in myocardial infarct size by postconditioning in patients after percutaneous coronary intervention. J Invasive Cardiol. 2007;19:424-430.
159. Laskey WK, Yoon S, Calzada N, Ricciardi MJ. Concordant improvements in coronary flow reserve and ST-segment resolution during percutaneous coronary intervention for acute myocardial infarction: A benefit of postconditioning. Catheter Cardiovasc Interv. 2008;72:212-220. doi: 10. 1002/ccd. 21583.
160. Garcia S, Henry TD, Wang YL, Chavez IJ, Pedersen WR, Lesser JR, Shroff GR, Moore L, Traverse JH. Long-term follow-up of patients undergoing postconditioning during ST-elevation myocardial infarction. J Cardiovasc Transl Res. 2011;4:92-98. doi: 10. 1007/ s12265-010-9252-0.
161. Liu TK, Mishra AK, Ding FX. [Protective effect of ischemia postconditioning on reperfusion injury in patients with ST-segment elevation acute myocardial infarction]. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39:35-39.
162. Thuny F, Lairez O, Roubille F, et al. Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2012;59:2175-2181. doi: 10. 1016/j. jacc. 2012. 03. 026.
163. Mewton N, Thibault H, Roubille F, et al. Postconditioning attenuates no-reflow in STEMI patients. Basic Res Cardiol. 2013;108:383. doi: 10. 1007/s00395-013-0383-8.
164. Araszkiewicz A, Grygier M, Pyda M, Rajewska J, Michalak M, Lesiak M, Grajek S. Postconditioning reduces enzymatic infarct size and improves microvascular reperfusion in patients with ST-segment elevation myocardial infarction. Cardiology. 2014;129:250-257. doi: 10. 1159/000367965.
165. Tarantini G, Favaretto E, Marra MP, Frigo AC, Napodano M, Cacciavillani L, Giovagnoni A, Renda P, De Biasio V, Plebani M, Mion M, Zaninotto M, Isabella G, Bilato C, Iliceto S. Postconditioning during coronary angioplasty in acute myocardial infarction: The POST-AMI trial. Int J Cardiol. 2012;162:33-38. doi: 10. 1016/j. ijcard. 2012. 03. 136.
166. Ugata Y, Nakamura T, Taniguchi Y, Ako J, Momomura S. Effect of postconditioning in patients with ST-elevation acute myocardial infarction. Cardiovasc Interv Ther. 2012;27:14-18. doi: 10. 1007/s12928-011-0077-9.
167. Dwyer NB, Mikami Y, Hilland D, Aljizeeri A, Friedrich MG, Traboulsi M, Anderson TJ. No cardioprotective benefit of ischemic postconditioning in patients with ST-segment elevation myocardial infarction. J Interv Cardiol. 2013;26:482-490. doi: 10. 1111/joic. 12064.
168. Hahn JY, Song YB, Kim EK, et al. Ischemic postconditioning during primary percutaneous coronary intervention: The effects of postconditioning on myocardial reperfusion in patients with ST-segment elevation myocardial infarction (POST) randomized trial. Circulation. 2013;128:1889-1896. doi: 10. 1161/CIRCULATIONAHA. 113. 001690.
169. Eitel I, Stiermaier T, Rommel KP, Fuernau G, Sandri M, Mangner N, Linke A, Erbs S, Lurz P, Boudriot E, Mende M, Desch S, Schuler G, Thiele H. Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: The randomized LIPSIA CONDITIONING trial. Eur Heart J. 2015;36:3049-3057. doi: 10. 1093/eurheartj/ehv463.
170. Kim EK, Hahn JY, Song YB, Lee SC, Choi JH, Choi SH, Lee SH, Choe YH, Gwon HC. Effect of ischemic postconditioning on myocardial salvage in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the POST randomized trial. Int J Cardiovasc Imaging. 2015;31:629-637. doi: 10. 1007/s10554-015-0589-y.
171. Loubeyre C, Morice MC, Lefevre T, Piechaud JF, Louvard Y, Dumas P. A randomized comparison of direct stenting with conventional stent implantation in selected patients with acute myocardial infarction. J Am Coll Cardiol. 2002;39:15-21.
172. Roubille F, Lairez O, Mewton N, Rioufol G, Ranc S, Sanchez I, Cung TT, Elbaz M, Piot C, Ovize M. Cardioprotection by clopidogrel in acute STelevated myocardial infarction patients: A retrospective analysis. Basic Res Cardiol. 2012;107:275. doi: 10. 1007/s00395-012-0275-3.
173. Cohen MV, Downey JM. Status of P2Y12 treatment must be considered in evaluation of myocardial ischaemia/reperfusion injury. Cardiovasc Res. 2015;106:8. doi: 10. 1093/cvr/cvv051.
174. Iliodromitis EK, Cohen MV, Dagres N, Andreadou I, Kremastinos DT, Downey JM. What is wrong with cardiac conditioning? We may be shooting at moving targets. J Cardiovasc Pharmacol Ther. 2015;20:357-369. doi: 10. 1177/1074248414566459.
175. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation. 1993;87:893-899.
176. Heusch G, Botker HE, Przyklenk K, Redington A, Yellon D. Remote ischemic conditioning. J Am Coll Cardiol. 2015;65:177-195. doi: 10. 1016/j. jacc. 2014. 10. 031.
177. Shimizu M, Konstantinov IE, Kharbanda RK, Cheung MH, Redington AN. Effects of intermittent lower limb ischaemia on coronary blood flow and coronary resistance in pigs. Acta Physiol (Oxf). 2007;190:103-109. doi: 10. 1111/j. 1748-1716. 2007. 01667. x.
178. Kono Y, Fukuda S, Hanatani A, Nakanishi K, Otsuka K, Taguchi H, Shimada K. Remote ischemic conditioning improves coronary microcirculation in healthy subjects and patients with heart failure. Drug Des Devel Ther. 2014;8:1175-1181. doi: 10. 2147/DDDT. S68715.
179. Hoole SP, Heck PM, White PA, Khan SN, O'Sullivan M, Clarke SC, Dutka DP. Remote ischemic preconditioning stimulus does not reduce microvascular resistance or improve myocardial blood flow in patients undergoing elective percutaneous coronary intervention. Angiology. 2009;60:403-411. doi: 10. 1177/0003319708328921.
180. Botker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: A randomised trial. Lancet. 2010;375:727-734. doi: 10. 1016/ S0140-6736(09)62001-8.
181. White SK, Frohlich GM, Sado DM, Maestrini V, Fontana M, Treibel TA, Tehrani S, Flett AS, Meier P, Ariti C, Davies JR, Moon JC, Yellon DM, Hausenloy DJ. Remote ischemic conditioning reduces myocardial infarct size and edema in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2015;8:178-188. doi: 10. 1016/j. jcin. 2014. 05. 015.
182. Crimi G, Pica S, Raineri C, et al. Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: A randomized controlled trial. JACC Cardiovasc Interv. 2013;6:1055-1063. doi: 10. 1016/j. jcin. 2013. 05. 011.
183. Pryds K, Botker HE. Influence of pre-infarction angina and coronary collateral circulation on the efficacy of remote ischaemic conditioning in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Eur Heart J Acute Cardiovasc Care. In press.
184. Shimizu M, Saxena P, Konstantinov IE, Cherepanov V, Cheung MM, Wearden P, Zhangdong H, Schmidt M, Downey GP, Redington AN. Remote ischemic preconditioning decreases adhesion and selectively modifies functional responses of human neutrophils. J Surg Res. 2010;158:155-161. doi: 10. 1016/j. jss. 2008. 08. 010.
185. Stazi A, Scalone G, Laurito M, Milo M, Pelargonio G, Narducci ML, Parrinello R, Figliozzi S, Bencardino G, Perna F, Lanza GA, Crea F. Effect of remote ischemic preconditioning on platelet activation and reactivity induced by ablation for atrial fibrillation. Circulation. 2014;129:11-17. doi: 10. 1161/CIRCULATIONAHA. 113. 005336.
186. Lanza GA, Stazi A, Villano A, Torrini F, Milo M, Laurito M, Flego D, Aurigemma C, Liuzzo G, Crea F. Effect of remote ischemic preconditioning on platelet activation induced by coronary procedures. Am J Cardiol. 2016;117:359-365. doi: 10. 1016/j. Amjcard. 2015. 10. 056.
187. Kleinbongard P, Schulz R, Rassaf T, et al. Red blood cells express a functional endothelial nitric oxide synthase. Blood. 2006;107:2943-2951. doi: 10. 1182/blood-2005-10-3992.
188. Grau M, Kollikowski A, Bloch W. Remote ischemia preconditioning increases red blood cell deformability through red blood cell-nitric oxide synthase activation [published online ahead of print January 27, 2016]. Clin Hemorheol Microcirc. 2016.
189. Heusch G, Libby P, Gersh B, Yellon D, Bohm M, Lopaschuk G, Opie L. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet. 2014;383:1933-1943. doi: 10. 1016/ S0140-6736(14)60107-0.
190. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev. 2014;66:1142-1174. doi: 10. 1124/pr. 113. 008300.
191. Schwartz Longacre L, Kloner RA, Arai AE, et al; National Heart, Lung, and Blood Institute, National Institutes of Health. New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation. 2011;124:1172-1179. doi: 10. 1161/CIRCULATIONAHA. 111. 032698.
192. Jones SP, Tang XL, Guo Y, et al. The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): A new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigs. Circ Res. 2015;116:572-586. doi: 10. 1161/CIRCRESAHA. 116. 305462.
193. Yetgin T, Uitterdijk A, Te Lintel Hekkert M, Merkus D, Krabbendam-Peters I, van Beusekom HM, Falotico R, Serruys PW, Manintveld OC, van Geuns RJ, Zijlstra F, Duncker DJ. Limitation of infarct size and no-reflow by intracoronary adenosine depends critically on dose and duration. JACC Cardiovasc Interv. 2015;8:1990-1999. doi: 10. 1016/j. jcin. 2015. 08. 033.
194. Zalewski J, Claus P, Bogaert J, Driessche NV, Driesen RB, Galan DT, Sipido KR, Buszman P, Milewski K, Van de Werf F. Cyclosporine A reduces microvascular obstruction and preserves left ventricular function deterioration following myocardial ischemia and reperfusion. Basic Res Cardiol. 2015;110:18. doi: 10. 1007/s00395-015-0475-8.
195. Sattler K, Graler M, Keul P, Weske S, Reimann CM, Jindrova H, Kleinbongard P, Sabbadini R, Brocker-Preuss M, Erbel R, Heusch G, Levkau B. Defects of high-density lipoproteins in coronary artery disease caused by low sphingosine-1-phosphate content: correction by sphingosine-1-phosphate-loading. J Am Coll Cardiol. 2015;66:1470-1485. doi: 10. 1016/j. jacc. 2015. 07. 057.
196. Vilahur G, Gutierrez M, Casani L, Cubedo J, Capdevila A, Pons-Llado G, Carreras F, Hidalgo A, Badimon L. Hypercholesterolemia abolishes high-density lipoprotein-related cardioprotective effects in the setting of myocardial infarction. J Am Coll Cardiol. 2015;66:2469-2470. doi: 10. 1016/j. jacc. 2015. 08. 901.
197. Li XD, Yang YJ, Geng YJ, Cheng YT, Zhang HT, Zhao JL, Yuan JQ, Gao RL. The cardioprotection of simvastatin in reperfused swine hearts relates to the inhibition of myocardial edema by modulating aquaporins via the PKA pathway. Int J Cardiol. 2013;167:2657-2666. doi: 10. 1016/j. ijcard. 2012. 06. 121.
198. Zhao JL, Yang YJ, Cui CJ, You SJ, Gao RL. Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial K(ATP) channel. Br J Pharmacol. 2006;149:243-249. doi: 10. 1038/sj. bjp. 0706862.
199. Dokken BB, La Bonte LR, Davis-Gorman G, Teachey MK, Seaver N, McDonagh PF. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res. 2011;43:300-305. doi: 10. 1055/s-0031-1271777.
200. Garcia-Dorado D, Theroux P, Munoz R, Alonso J, Elizaga J, Fernandez-Aviles F, Botas J, Solares J, Soriano J, Duran JM. Favorable effects of hyperosmotic reperfusion on myocardial edema and infarct size. Am J Physiol. 1992;262:H17-H22.
201. Uitterdijk A, Yetgin T, te Lintel Hekkert M, Sneep S, Krabbendam-Peters I, van Beusekom HM, Fischer TM, Cornelussen RN, Manintveld OC, Merkus D, Duncker DJ. Vagal nerve stimulation started just prior to reperfusion limits infarct size and no-reflow. Basic Res Cardiol. 2015;110:508. doi: 10. 1007/s00395-015-0508-3.
202. Pierrakos CN, Bonios MJ, Drakos SG, Charitos EI, Tsolakis EJ, Ntalianis A, Nanas SN, Charitos CE, Nanas JN, Terrovitis JV. Mechanical assistance by intra-aortic balloon pump counterpulsation during reperfusion increases coronary blood flow and mitigates the no-reflow phenomenon: An experimental study. Artif Organs. 2011;35:867-874. doi: 10. 1111/j. 1525-1594. 2011. 01241. x.
203. Pantsios C, Kapelios C, Vakrou S, Diakos N, Pozios I, Kontogiannis C, Nanas J, Malliaras K. Effect of elevated reperfusion pressure on "no reflow" area and infarct size in a porcine model of ischemia-reperfusion [published online ahead of print November 20, 2015]. J Cardiovasc Pharmacol Ther. 2015.
204. Herring MJ, Dai W, Hale SL, Kloner RA. Rapid induction of hypothermia by the ThermoSuit system profoundly reduces infarct size and anatomic zone of no reflow following ischemia-reperfusion in rabbit and rat hearts. J Cardiovasc Pharmacol Ther. 2015;20:193-202. doi: 10. 1177/1074248414535664.
205. Hale SL, Herring MJ, Kloner RA. Delayed treatment with hypothermia protects against the no-reflow phenomenon despite failure to reduce infarct size. J Am Heart Assoc. 2013;2:e004234. doi: 10. 1161/JAHA. 112. 004234.
206. Kanazawa H, Tseliou E, Malliaras K, et al. Cellular postconditioning: Allogeneic cardiosphere-derived cells reduce infarct size and attenuate microvascular obstruction when administered after reperfusion in pigs with acute myocardial infarction. Circ Heart Fail. 2015;8:322-332. doi: 10. 1161/CIRCHEARTFAILURE. 114. 001484.
207. Gerczuk PZ, Kloner RA. An update on cardioprotection: A review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J Am Coll Cardiol. 2012;59:969-978. doi: 10. 1016/j. jacc. 2011. 07. 054.
208. Dixon SR, Whitbourn RJ, Dae MW, Grube E, Sherman W, Schaer GL, Jenkins JS, Baim DS, Gibbons RJ, Kuntz RE, Popma JJ, Nguyen TT, O'Neill WW. Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol. 2002;40:1928-1934.
209. Gotberg M, Olivecrona GK, Koul S, Carlsson M, Engblom H, Ugander M, van der Pals J, Algotsson L, Arheden H, Erlinge D. A pilot study of rapid cooling by cold saline and endovascular cooling before reperfusion in patients with ST-elevation myocardial infarction. Circ Cardiovasc Interv. 2010;3:400-407. doi: 10. 1161/CIRCINTERVENTIONS. 110. 957902.
210. Erlinge D, Gotberg M, Lang I, et al. Rapid endovascular catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. The CHILL-MI trial: A randomized controlled study of the use of central venous catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. J Am Coll Cardiol. 2014;63:1857-1865. doi: 10. 1016/j. jacc. 2013. 12. 027.
211. Nichol G, Strickland W, Shavelle D, et al; VELOCITY Investigators. Prospective, multicenter, randomized, controlled pilot trial of peritoneal hypothermia in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2015;8:e001965. doi: 10. 1161/ CIRCINTERVENTIONS. 114. 001965.
212. O'Neill WW, Martin JL, Dixon SR, Bartorelli AL, Trabattoni D, Oemrawsingh PV, Atsma DE, Chang M, Marquardt W, Oh JK, Krucoff MW, Gibbons RJ, Spears JR; AMIHOT Investigators. Acute Myocardial Infarction with Hyperoxemic Therapy (AMIHOT): A prospective, randomized trial of intracoronary hyperoxemic reperfusion after percutaneous coronary intervention. J Am Coll Cardiol. 2007;50:397-405. doi: 10. 1016/j. jacc. 2007. 01. 099.
213. Stone GW, Martin JL, de Boer MJ, Margheri M, Bramucci E, Blankenship JC, Metzger DC, Gibbons RJ, Lindsay BS, Weiner BH, Lansky AJ, Krucoff MW, Fahy M, Boscardin WJ; AMIHOT-II Trial Investigators. Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. Circ Cardiovasc Interv. 2009;2:366-375. doi: 10. 1161/ CIRCINTERVENTIONS. 108. 840066.
214. Antoniucci D, Valenti R, Migliorini A, Parodi G, Memisha G, Santoro GM, Sciagra R. Comparison of rheolytic thrombectomy before direct infarct artery stenting versus direct stenting alone in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2004;93:1033-1035. doi: 10. 1016/j. Amjcard. 2004. 01. 011.
215. Kaltoft A, Bottcher M, Nielsen SS, et al. Routine thrombectomy in percutaneous coronary intervention for acute ST-segment-elevation myocardial infarction: A randomized, controlled trial. Circulation. 2006;114:40-47. doi: 10. 1161/CIRCULATIONAHA. 105. 595660.
216. Lipiecki J, Monzy S, Durel N, Cachin F, Chabrot P, Muliez A, Morand D, Maublant J, Ponsonnaille J. Effect of thrombus aspiration on infarct size and left ventricular function in high-risk patients with acute myocardial infarction treated by percutaneous coronary intervention. Results of a prospective controlled pilot study. Am Heart J. 2009;157:583. e1-583. e7. doi: 10. 1016/j. Ahj. 2008. 11. 017.
217. Sardella G, Mancone M, Bucciarelli-Ducci C, Agati L, Scardala R, Carbone I, Francone M, Di Roma A, Benedetti G, Conti G, Fedele F. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: The EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial. J Am Coll Cardiol. 2009;53:309-315. doi: 10. 1016/j. jacc. 2008. 10. 017.
218. Migliorini A, Stabile A, Rodriguez AE, Gandolfo C, Rodriguez Granillo AM, Valenti R, Parodi G, Neumann FJ, Colombo A, Antoniucci D; JETSTENT Trial Investigators. Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction. The JETSTENT trial. J Am Coll Cardiol. 2010;56:1298-1306. doi: 10. 1016/j. jacc. 2010. 06. 011.
219. Ciszewski M, Pregowski J, Teresinska A, Karcz M, Kalinczuk ?, Pracon R, Witkowski A, Ru'yo W. Aspiration coronary thrombectomy for acute myocardial infarction increases myocardial salvage: single center randomized study. Catheter Cardiovasc Interv. 2011;78:523-531. doi: 10. 1002/ccd. 22933.
220. De Carlo M, Aquaro GD, Palmieri C, Guerra E, Misuraca L, Giannini C, Lombardi M, Berti S, Petronio AS. A prospective randomized trial of thrombectomy versus no thrombectomy in patients with ST-segment elevation myocardial infarction and thrombus-rich lesions: MUSTELA (MUltidevice Thrombectomy in Acute ST-Segment ELevation Acute Myocardial Infarction) trial. JACC Cardiovasc Interv. 2012;5:1223-1230. doi: 10. 1016/j. jcin. 2012. 08. 013.
221. Stone GW, Maehara A, Witzenbichler B, et al; INFUSE-AMI Investigators. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: The INFUSEAMI randomized trial. JAMA. 2012;307:1817-1826. doi: 10. 1001/ jama. 2012. 421.
222. Patel MR, Smalling RW, Thiele H, Barnhart HX, Zhou Y, Chandra P, Chew D, Cohen M, French J, Perera D, Ohman EM. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: The CRISP AMI randomized trial. JAMA. 2011;306:1329-1337. doi: 10. 1001/jama. 2011. 1280.
223. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473-481. doi: 10. 1056/NEJMoa071142.
224. Ghaffari S, Kazemi B, Toluey M, Sepehrvand N. The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction. Cardiovasc Ther. 2013;31:e34-e39. doi: 10. 1111/1755-5922. 12010.
225. Cung TT, Morel O, Cayla G, et al. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med. 2015;373:1021-1031. doi: 10. 1056/NEJMoa1505489.
226. Ottani F, Latini R, Staszewsky L, et al; CYCLE Investigators. Cyclosporine A in reperfused myocardial infarction: The multicenter, controlled, open-label CYCLE trial. J Am Coll Cardiol. 2016;67:365-374. doi: 10. 1016/j. jacc. 2015. 10. 081.
227. Heusch G. CIRCUS: A kiss of death for cardioprotection? Cardiovasc Res. 2015;108:215-216. doi: 10. 1093/cvr/cvv225.
228. Thiele H, Schindler K, Friedenberger J, Eitel I, Furnau G, Grebe E, Erbs S, Linke A, Mobius-Winkler S, Kivelitz D, Schuler G. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: The randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation. 2008;118:49-57. doi: 10. 1161/ CIRCULATIONAHA. 107. 747642.
229. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000;101:2154-2159.
230. Niccoli G, Rigattieri S, De Vita MR, et al. Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: The REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction). JACC Cardiovasc Interv. 2013;6:580-589. doi: 10. 1016/j. jcin. 2013. 02. 009.
231. Fokkema ML, Vlaar PJ, Vogelzang M, Gu YL, Kampinga MA, de Smet BJ, Jessurun GA, Anthonio RL, van den Heuvel AF, Tan ES, Zijlstra F. Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: A randomized controlled trial. Circ Cardiovasc Interv. 2009;2:323-329. doi: 10. 1161/CIRCINTERVENTIONS. 109. 858977. 109. 858977.
232. Garcia-Dorado D, Garcia-del-Blanco B, Otaegui I, Rodriguez-Palomares J, Pineda V, Gimeno F, Ruiz-Salmeron R, Elizaga J, Evangelista A, Fernandez-Aviles F, San-Roman A, Ferreira-Gonzalez I. Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: A randomized controlled clinical trial. Int J Cardiol. 2014;177:935-941. doi: 10. 1016/j. ijcard. 2014. 09. 203.
233. Siddiqi N, Neil C, Bruce M, et al; NIAMI investigators. Intravenous sodium nitrite in acute ST-elevation myocardial infarction: A randomized controlled trial (NIAMI). Eur Heart J. 2014;35:1255-1262. doi: 10. 1093/eurheartj/ehu096.
234. Jones DA, Pellaton C, Velmurugan S, Rathod KS, Andiapen M, Antoniou S, van Eijl S, Webb AJ, Westwood MA, Parmar MK, Mathur A, Ahluwalia A. Randomized phase 2 trial of intracoronary nitrite during acute myocardial infarction. Circ Res. 2015;116:437-447. doi: 10. 1161/ CIRCRESAHA. 116. 305082.
235. Ott I, Schulz S, Mehilli J, Fichtner S, Hadamitzky M, Hoppe K, Ibrahim T, Martinoff S, Massberg S, Laugwitz KL, Dirschinger J, Schwaiger M, Kastrati A, Schmig A; REVIVAL-3 Study Investigators. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, double-blind trial. Circ Cardiovasc Interv. 2010;3:408-413. doi: 10. 1161/ CIRCINTERVENTIONS. 109. 904425.
236. Atar D, Arheden H, Berdeaux A, et al. Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. Eur Heart J. 2015;36:112-119. doi: 10. 1093/eurheartj/ehu331.
237. Gibson CM, Giugliano RP, Kloner RA, et al. EMBRACE STEMI study: A Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J. 2015;10. 1093/eurheartj/ ehv597
238. Kitakaze M, Asakura M, Kim J, et al; J-WIND investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): Two randomised trials. Lancet. 2007;370:1483-1493. doi: 10. 1016/ S0140-6736(07)61634-1.
239. Er F, Dahlem KM, Nia AM, et al. Randomized control of sympathetic drive with continuous intravenous esmolol in patients with acute STsegment elevation myocardial infarction: The BEtA-Blocker Therapy in Acute Myocardial Infarction (BEAT-AMI) trial. JACC Cardiovasc Interv. 2016;9:231-240. doi: 10. 1016/j. jcin. 2015. 10. 035.
240. Lonborg J, Kelbak H, Vejlstrup N, Botker HE, Kim WY, Holmvang L, Jorgensen E, Helqvist S, Saunamaki K, Terkelsen CJ, Schoos MM, Kober L, Clemmensen P, Treiman M, Engstrom T. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv. 2012;5:288-295. doi: 10. 1161/CIRCINTERVENTIONS. 112. 968388.
241. Lonborg J, Vejlstrup N, Kelbak H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:1491-1499. doi: 10. 1093/eurheartj/ehr309.
242. Woo JS, Kim W, Ha SJ, Kim JB, Kim SJ, Kim WS, Seon HJ, Kim KS. Cardioprotective effects of exenatide in patients with ST-segmentelevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol. 2013;33:2252-2260. doi: 10. 1161/ATVBAHA. 113. 301586.
243. Reffelmann T, Hale SL, Li G, Kloner RA. Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2002;282:H766-H772. doi: 10. 1152/ajpheart. 00767. 2001.
244. Reffelmann T, Kloner RA. Microvascular reperfusion injury: rapid expansion of anatomic no reflow during reperfusion in the rabbit. Am J Physiol Heart Circ Physiol. 2002;283:H1099-H1107. doi: 10. 1152/ ajpheart. 00270. 2002.
245. Reffelmann T, Kloner RA. Is microvascular protection by cariporide and ischemic preconditioning causally linked to myocardial salvage? Am J Physiol Heart Circ Physiol. 2003;284:H1134-H1141. doi: 10. 1152/ ajpheart. 00563. 2002.
246. Heusch G, Kleinbongard P, Skyschally A. Myocardial infarction and coronary microvascular obstruction: An intimate, but complicated relationship. Basic Res Cardiol. 2013;108:380. doi: 10. 1007/ s00395-013-0380-y.
247. Kloner RA, Rude RE, Carlson N, Maroko PR, DeBoer LW, Braunwald E. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first? Circulation. 1980;62:945-952.
248. Sanz E, Garcia Dorado D, Oliveras J, Barrabes JA, Gonzalez MA, Ruiz-Meana M, Solares J, Carreras MJ, Garcia-Lafuente A, Desco M. Dissociation between anti-infarct effect and anti-edema effect of ischemic preconditioning. Am J Physiol. 1995;268:H233-H241.
249. Hori M, Gotoh K, Kitakaze M, Iwai K, Iwakura K, Sato H, Koretsune Y, Inoue M, Kitabatake A, Kamada T. Role of oxygen-derived free radicals in myocardial edema and ischemia in coronary microvascular embolization. Circulation. 1991;84:828-840.
250. Guarini G, Kiyooka T, Ohanyan V, et al. Impaired coronary metabolic dilation in the metabolic syndrome is linked to mitochondrial dysfunction and mitochondrial DNA damage. Basic Res Cardiol. 2016;111:29. doi: 10. 1007/s00395-016-0547-4.